Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia

被引:179
作者
Lugthart, Sanne
Groschel, Stefan
Beverloo, H. Berna
Kayser, Sabine
Valk, Peter J. M.
van Zelderen-Bhola, Shama Lydia
Ossenkoppele, Gert Jan
Vellenga, Edo
van den Berg-de Ruiter, Eva
Schanz, Urs
Verhoef, Gregor
Vandenberghe, Peter
Ferrant, Augustin
Kohne, Claus-Henning
Pfreundschuh, Michael
Horst, Heinz A.
Koller, Elisabeth
von Lilienfeld-Toal, Marie
Bentz, Martin
Ganser, Arnold
Schlegelberger, Brigitte
Jotterand, Martine
Krauter, Jurgen
Pabst, Thomas
Theobald, Matthias
Schlenk, Richard F.
Delwel, Ruud
Dohner, Konstanze
Lowenberg, Bob
Doehner, Hartmut [1 ]
机构
[1] Univ Hosp, Dept Internal Med 3, Ulm, Germany
关键词
BONE-MARROW-TRANSPLANTATION; ACUTE MYELOGENOUS LEUKEMIAS; COLONY-STIMULATING FACTOR; ADULT PATIENTS; CYTOGENETIC ABNORMALITIES; POSTREMISSION THERAPY; NORMAL-TISSUES; EXPRESSION; DIAGNOSIS; CANCER;
D O I
10.1200/JCO.2010.29.2771
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Acute myeloid leukemia (AML) with inv(3)(q21q26.2)/t(3; 3)(q21; q26.2) inv(3)/t(3; 3)] is recognized as a distinctive entity in the WHO classification. Risk assignment and clinical and genetic characterization of AML with chromosome 3q abnormalities other than inv(3)/t(3; 3) remain largely unresolved. Patients and Methods Cytogenetics, molecular genetics, therapy response, and outcome analysis were performed in 6,515 newly diagnosed adult AML patients. Patients were treated on Dutch-Belgian HematoOncology Cooperative Group/Swiss Group for Clinical Cancer Research (HOVON/SAKK; n = 3,501) and German-Austrian Acute Myeloid Leukemia Study Group (AMLSG; n = 3,014) protocols. EVI1 and MDS1/EVI1 expression was determined by real-time quantitative polymerase chain reaction. Results 3q abnormalities were detected in 4.4% of AML patients (288 of 6,515). Four distinct groups were defined: A: inv(3)/t(3; 3), 32%; B: balanced t(3q26), 18%; C: balanced t(3q21), 7%; and D: other 3q abnormalities, 43%. Monosomy 7 was the most common additional aberration in groups (A), 66%; (B), 31%; and (D), 37%. N-RAS mutations and dissociate EVI1 versus MDS1/EVI1 overexpression were associated with inv(3)/t(3; 3). Patients with inv(3)/t(3; 3) and balanced t(3q21) at diagnosis presented with higher WBC and platelet counts. In multivariable analysis, only inv(3)/t(3; 3), but not t(3q26) and t(3q21), predicted reduced relapse-free survival (hazard ratio [HR], 1.99; P<.001) and overall survival (HR, 1.4; P=.006). This adverse prognostic impact of inv(3)/t(3; 3) was enhanced by additional monosomy 7. Group D 3q aberrant AML also had a poor outcome related to the coexistence of complex and/or monosomal karyotypes and cryptic inv(3)/t(3; 3). Conclusion Various categories of 3q abnormalities in AML can be distinguished according to their clinical, hematologic, and genetic features. AML with inv(3)/t(3; 3) represents a distinctive subgroup with unfavorable prognosis.
引用
收藏
页码:3890 / 3898
页数:9
相关论文
共 39 条
  • [1] Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission:: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial
    Breems, DA
    Boogaerts, MA
    Dekker, AW
    Van Putten, WLJ
    Sonneveld, P
    Huijgens, PC
    Van der Lelie, J
    Vellenga, E
    Gratwohl, A
    Verhoef, GEG
    Verdonck, LF
    Löwenberg, B
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (01) : 59 - 65
  • [2] Monosomal karyotype in acute myeloid leukemia:: A better indicator of poor prognosis than a complex karyotype
    Breems, Dimitri A.
    Van Putten, Wim L. J.
    De Greef, Georgine E.
    Van Zelderen-Bhola, Shama L.
    Gerssen-Schoorl, Klasien B. J.
    Mellink, Clemens H. M.
    Nieuwint, Aggie
    Jotterand, Martine
    Hagemeijer, Anne
    Beverloo, H. Berna
    Lowenberg, Bob
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) : 4791 - 4797
  • [3] Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461)
    Byrd, JC
    Mrózek, K
    Dodge, RK
    Carroll, AJ
    Edwards, CG
    Arthur, DC
    Pettenati, MJ
    Patil, SR
    Rao, KW
    Watson, MS
    Koduru, PRK
    Moore, JO
    Stone, RM
    Mayer, RJ
    Feldman, EJ
    Davey, FR
    Schiffer, CA
    Larson, RA
    Bloomfield, CD
    [J]. BLOOD, 2002, 100 (13) : 4325 - 4336
  • [4] Charrin Christiane, 2002, Hematol J, V3, P21, DOI 10.1038/sj.thj.6200143
  • [5] REPORT OF THE NATIONAL CANCER INSTITUTE-SPONSORED WORKSHOP ON DEFINITIONS OF DIAGNOSIS AND RESPONSE IN ACUTE MYELOID-LEUKEMIA
    CHESON, BD
    CASSILETH, PA
    HEAD, DR
    SCHIFFER, CA
    BENNETT, JM
    BLOOMFIELD, CD
    BRUNNING, R
    GALE, RP
    GREVER, MR
    KEATING, MJ
    SAWITSKY, A
    STASS, S
    WEINSTEIN, H
    WOODS, WG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (05) : 813 - 819
  • [6] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
    Cheson, BD
    Bennett, JM
    Kopecky, KJ
    Büchner, T
    Willman, CL
    Estey, EH
    Schiffer, CA
    Döhner, H
    Tallman, MS
    Lister, TA
    LoCocco, F
    Willemze, R
    Biondi, A
    Hiddemann, W
    Larson, RA
    Löwenberg, B
    Sanz, MA
    Head, DR
    Ohno, R
    Bloomfield, CD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) : 4642 - 4649
  • [7] Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
    Doehner, Hartmut
    Estey, Elihu H.
    Amadori, Sergio
    Appelbaum, Frederick R.
    Buechner, Thomas
    Burnett, Alan K.
    Dombret, Herve
    Fenaux, Pierre
    Grimwade, David
    Larson, Richard A.
    Lo-Coco, Francesco
    Naoe, Tomoki
    Niederwieser, Dietger
    Ossenkoppele, Gert J.
    Sanz, Miguel A.
    Sierra, Jorge
    Tallman, Martin S.
    Loewenberg, Bob
    Bloomfield, Clara D.
    [J]. BLOOD, 2010, 115 (03) : 453 - 474
  • [8] Acute myeloid leukaemia
    Estey, Elihu
    Doehner, Hartmut
    [J]. LANCET, 2006, 368 (9550) : 1894 - 1907
  • [9] Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family
    Fears, S
    Mathieu, C
    ZeleznikLe, N
    Huang, S
    Rowley, JD
    Nucifora, G
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (04) : 1642 - 1647
  • [10] GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515